ING Groep NV bought a new stake in Radius Health Inc (NASDAQ:RDUS) in the second quarter, Holdings Channel reports. The fund bought 221,753 shares of the biopharmaceutical company’s stock, valued at approximately $6,535,000.

A number of other hedge funds also recently modified their holdings of RDUS. NumerixS Investment Technologies Inc acquired a new position in Radius Health in the second quarter valued at approximately $162,000. Xact Kapitalforvaltning AB acquired a new position in Radius Health in the first quarter valued at approximately $213,000. Aperio Group LLC acquired a new position in Radius Health in the first quarter valued at approximately $231,000. Sofinnova Ventures Inc acquired a new position in Radius Health in the first quarter valued at approximately $605,000. Finally, Price Capital Management Inc. acquired a new position in Radius Health in the second quarter valued at approximately $674,000.

In other news, major shareholder Growth N. V. Biotech bought 169,363 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were purchased at an average price of $20.83 per share, with a total value of $3,527,831.29. Following the completion of the acquisition, the insider now directly owns 6,460,913 shares in the company, valued at $134,580,817.79. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 25th. The shares were purchased at an average cost of $27.28 per share, for a total transaction of $1,364,000.00. Following the acquisition, the insider now owns 6,250,913 shares of the company’s stock, valued at $170,524,906.64. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 439,363 shares of company stock worth $10,043,131. Corporate insiders own 3.42% of the company’s stock.

A number of equities analysts have commented on RDUS shares. JPMorgan Chase & Co. decreased their target price on Radius Health from $60.00 to $59.00 and set a “$28.40” rating for the company in a research note on Monday, July 23rd. Bank of America decreased their target price on Radius Health from $51.00 to $47.00 and set a “buy” rating for the company in a research note on Wednesday, July 25th. Cantor Fitzgerald set a $58.00 target price on Radius Health and gave the company a “buy” rating in a research note on Monday, June 11th. BidaskClub downgraded Radius Health from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 6th. Finally, ValuEngine downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $48.63.

RDUS opened at $19.74 on Friday. The company has a market cap of $936.82 million, a PE ratio of -3.40 and a beta of 1.04. The company has a current ratio of 5.39, a quick ratio of 5.26 and a debt-to-equity ratio of 1.26. Radius Health Inc has a twelve month low of $18.88 and a twelve month high of $41.16.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.35) by $0.36. The company had revenue of $22.63 million for the quarter, compared to analysts’ expectations of $20.84 million. Radius Health had a negative return on equity of 110.71% and a negative net margin of 444.70%. analysts anticipate that Radius Health Inc will post -5.42 earnings per share for the current year.

Radius Health Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.

See Also: Why Dividend Stocks May Be Right for You

Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.